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Abstract 11 
The misuse of benzodiazepines as new psychoactive substances is an increasing problem 12 
around the world. Basic physicochemical and pharmacokinetic data is required on these 13 
substances in order to interpret and predict their effects upon humans. Experimental log D7.4, 14 
pKa and plasma protein binding values were determined for 11 benzodiazepines that have 15 
recently appeared as new psychoactive substances (3-Hydroxyphenazepam, 4’-16 
Chlorodiazepam, desalkylflurazepam, deschloroetizolam, diclazepam, etizolam, 17 
flubromazepam, flubromazolam, meclonazepam, phenazepam and pyrazolam) and compared 18 
with values generated by various software packages (ACD/I-lab, MarvinSketch, ADMET 19 
Predictor and PreADMET). ACD/I-LAB returned the most accurate values for log D7.4 and 20 
plasma protein binding while ADMET Predictor returned the most accurate values for pKa. 21 
Large variations in predictive errors were observed between compounds. Experimental values 22 
are currently preferable and desirable as they may aid with the future ‘training’ of predictive 23 
models for these new psychoactive substances. 24 
 25 
 26 
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1. Introduction 29 
New psychoactive substances (NPS) are an increasing problem around the world [1]. 30 
Benzodiazepines are one of a number of groups of NPS that have appeared on the illicit drug 31 
market [2]. They also exist as common prescription drugs for anxiety, insomnia and other 32 
medical conditions [3]. Benzodiazepines were misused long before emerging as new 33 
psychoactive substances and a recent report highlighted the increasing illicit availability and 34 
misuse of a clinically-used benzodiazepine, alprazolam, often purchased from the dark web 35 
[4]. The new psychoactive substance benzodiazepines (referred to in this work as NPS-36 
benzodiazepines) have already been reported in a number of overdose cases, driving under the 37 
influence of drugs (DUID) cases and hospital admissions [5–8]. The lack of control and safety 38 
over these NPS-benzodiazepines is a prevalent issue and it is predicted that it will become an 39 
even more worrying trend as their misuse continues to rise. A number of these compounds 40 
were originally prescription drugs such as phenazepam (Russia) as well as etizolam and 41 
flutazolam (Japan) [9–11]. Some of these compounds never gained marketing approval (e.g. 42 
adinazolam) but the majority were simply patented and never brought to market and, as such, 43 
there is a deficit of physiochemical and pharmacokinetic data that would otherwise exist if they 44 
had undergone clinical trials [12]. However, such information is essential to fully understand 45 
the pharmacological behaviour of these compounds, especially as they are becoming more and 46 
more prevalent on the illicit drug market. This paper focuses on two physiochemical properties 47 
(log D7.4 and pKa) and one pharmacokinetic property (plasma protein binding). 48 
The lipophilicity of a compound is often expressed by the term log D7.4, this is the distribution 49 
coefficient and represents the relative ratios of a compound in an organic and aqueous solvent 50 
at the physiologically-relevant pH of 7.4 [13]. Lipophilicity has various pharmacokinetic 51 
implications such as affecting a compound’s absorption through cell membranes and its 52 
distribution in biological tissues and accordingly is important for the prediction of many of 53 
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these pharmacokinetic parameters [14,15]. Highly-lipophilic compounds typically exhibit 54 
greater plasma protein binding and can generally cross the blood-brain barrier with greater ease 55 
[16,17]. The majority of the well-known, from herein referred to as ‘classic’, benzodiazepines 56 
have comparatively high values for lipophilicity and can therefore partition with ease across 57 
cellular membranes and accumulate in areas of the body that are high in lipids [18,19]. 58 
Furthermore, benzodiazepines also have high volumes of distribution (Vd) such as diazepam 59 
with a Vd at steady state of 0.88 – 1.39 L kg-1 [20–23]. The lipophilicity (as log P) of some 60 
NPS-benzodiazepines has already been published in literature [24]. 61 
The acid-base dissociation constant (pKa) of a compound is typically investigated during 62 
pharmaceutical development and plays an important role when used in conjunction with other 63 
parameters such as molecular weight and lipophilicity [25]. pKa can affect the site in the body 64 
where compounds are absorbed [26] and can also assist with the development of extraction 65 
methods from biological samples [27].  66 
Upon administration to the body, compounds bind to proteins present within the plasma, this 67 
is reflected through measurement of plasma protein binding values [28,29].  The fraction that 68 
is not bound (known as the unbound or free fraction) is responsible for the pharmacological 69 
effect and it is this fraction that undergoes metabolism and excretion [18]. The majority of the 70 
classic benzodiazepines are highly protein-bound such as diazepam (99 % bound) but some 71 
experience vastly lower binding, for example bromazepam (60 % bound) [30,31]. Reducing 72 
clearance (Cl) and increased plasma protein binding generally correlates with an increase in 73 
half-life (t1/2) of a drug [32].  Knowledge of plasma protein binding is therefore important to 74 
help characterise pharmacokinetics of drugs without in vivo studies. There has already been 75 
interest in the determination of these properties for new psychoactive substances, for example 76 
the plasma protein binding of flubromazolam (89 %) has recently been published in the 77 
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literature [33]. Yet for many of the more recently synthesised benzodiazepines the percentage 78 
bound is as yet unknown.  79 
As many of these compounds have never undergone clinical trials, and are unlikely to as a 80 
result of the time and expense involved, it is critical that such analysis is undertaken, especially 81 
for the future prediction of any newly emerging psychoactive substances. The use of predictive 82 
software could be an attractive alternative to in vitro experiments to calculate these properties 83 
and this research will focus upon comparison of some predictive software packages with 84 
experimental values. 85 
2. Materials and methods 86 
Eight benzodiazepines that had values available in the literature for log D7.4, pKa and plasma 87 
protein binding were chosen to examine the suitability of the devised methods (alprazolam, 88 
clonazepam, diazepam, flunitrazepam, nitrazepam, oxazepam, prazepam and temazepam). 89 
These three properties were then investigated experimentally for a further 11, as yet, 90 
uncharacterised benzodiazepines, recently appearing as new psychoactive substances (3-91 
Hydroxyphenazepam, 4’-Chlorodiazepam, desalkylflurazepam, deschloroetizolam, 92 
diclazepam, etizolam, flubromazepam, flubromazolam, meclonazepam, phenazepam and 93 
pyrazolam). The chemical structures of this latter group of compounds can be found in the 94 
Supplementary Information.  95 
2.1. Materials 96 
4’-Chlorodiazepam, alprazolam, clonazepam, desalkylflurazepam, diazepam, flunitrazepam, 97 
nitrazepam, oxazepam, prazepam and temazepam were obtained from Sigma-Aldrich (Dorset, 98 
UK). 3-Hydroxyphenazepam, deschloroetizolam, diclazepam, etizolam, flubromazepam, 99 
flubromazolam, meclonazepam, phenazepam and pyrazolam were obtained from Chiron 100 
(Trondheim, Norway). All compounds were received as powdered solids. 101 
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Dimethyl sulfoxide (DMSO), methanol, phosphoric acid, sodium hydrogen phosphate 102 
heptahydrate, sodium dihydrogen phosphate, disodium hydrogen phosphate, acetic acid, 103 
sodium acetate trihydrate, boric acid, sodium hydroxide, hydrochloric acid, sodium chloride 104 
and octan-1-ol were purchased from Fisher Scientific (Leicestershire, UK). Phosphate buffered 105 
saline (PBS) tablets were purchased from Sigma-Aldrich (Dorset, UK).  106 
Human plasma (pooled, from three male donors and three female donors) was obtained from 107 
Seralab (West Sussex, UK). Plasma was received frozen with sodium citrate as an 108 
anticoagulant. 109 
2.2. Methods 110 
2.2.1. Determination of log D7.4 111 
The shake-flask method is commonly used in determining log D7.4 values [34]. The compound 112 
of interest is dissolved in equal volumes of a buffer at a specified pH and an organic solvent, 113 
such as octanol. Following equilibration the octanol and buffer are separated and the 114 
concentration of the compound in each is determined. The log D7.4 is then calculated using 115 
Equation 1. 116 
 
𝑙𝑜𝑔𝐷 =
𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑎𝑞𝑢𝑒𝑜𝑢𝑠 𝑝ℎ𝑎𝑠𝑒
𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑜𝑟𝑔𝑎𝑛𝑖𝑐 𝑝ℎ𝑎𝑠𝑒
 
(1) 
   
Sodium phosphate buffer (0.01 M) was formulated using deionised water (Barnstead 117 
UltraPure) and filtered through a 0.45 µm Nylon Phenex filter membrane (Phenomenex, 118 
Cheshire, UK) using a Millipore filtration apparatus (Merck Millipore, Hertfordshire, UK).  119 
Compounds were dissolved in methanol at a concentration of 1 mg ml-1. Aliquots of compound 120 
solution were evaporated with a flow of nitrogen using a TurboVap to yield 0.20 mg of 121 
compound. Equal volumes (700 µl) of sodium phosphate buffer (0.01 M, pH 7.4) and octan-1-122 
ol were added and the samples were vortexed for 30 seconds. 123 
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The samples were transferred into 1.5 mL Eppendorf microcentrifuge tubes and placed on a 124 
Stuart SB3 rotator (Bibby Scientific, Staffordshire UK) and rotated at 40 rpm for four hours. 125 
Samples were then centrifuged at 10,000 rpm for 20 minutes. The separated octanol and buffer 126 
phases were collected and analysed using high performance liquid chromatography (HPLC) 127 
coupled to a diode array detector (DAD). Further details of the method employed are given in 128 
Section 2.4. Each log D determination was repeated in triplicate. 129 
2.2.2. Determination of pKa 130 
Capillary electrophoresis is a common method of measuring pKa [35]. The basic principle 131 
behind this technique is an applied electrical voltage which separates ions according to their 132 
electrophoretic mobility. When the solute is unionised it has no mobility and when an electrical 133 
voltage is applied and it is fully ionised it has maximum electrophoretic mobility. The mobility 134 
of the solute between these two extremes is a function of the dissociation equilibrium. The 135 
effective electrophoretic mobility of a compound can be calculated by using the difference in 136 
migration time between the test compound and a neutral marker [35]. 137 
 𝜇𝑒𝑓𝑓 = (
𝐿𝑑𝐿𝑡
𝑉
) (
1
𝑡𝑎
−
1
𝑡𝑚
) (2) 
In Equation , ta is the migration time for the test compound (s), tm is the migration time for the 138 
neutral marker (s), Ld is the total length from the capillary inlet to the detection window (cm), 139 
Lt is the total capillary length (cm) and V is the applied voltage (V). As a result of the differences 140 
in pH there can be variations in electroosmotic flow but these are corrected for by using a 141 
neutral compound as a marker and adjusting for this in the calculation of effective mobility.  142 
𝜇𝑒𝑓𝑓 =
𝛼 × 10−𝑝𝐻
10−𝑝𝐾𝑎 + 10−𝑝𝐻
 (3) 
𝜇𝑒𝑓𝑓 =
𝑏1(10
−𝑝𝐻)2 + 𝑎110
−𝑝𝐾𝑎1 10−𝑝𝐾𝑎2
(10−𝑝𝐻)2 + 10−𝑝𝐾𝑎110−𝑝𝐻 + 10−𝑝𝐾𝑎110−𝑝𝐾𝑎2
 (4) 
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Equations (3) and (4) describe the relationship between the effective electrophoretic mobility 143 
of a compound and its pKa for benzodiazepines with one ionisable basic group and an ionisable 144 
basic and acidic group [36].  145 
Phosphate, acetate and borate buffers were utilised as described elsewhere with a pH spacing 146 
of 0.5 pH units [36]. All buffers had an ionic strength of I=0.05 and a concentration of 0.05 M. 147 
Sodium chloride was used to adjust the ionic strength and hydrochloric acid (0.1 M) or sodium 148 
hydroxide (0.1 M) were used to adjust the pH values if necessary. The pH was measured with 149 
a Jenway 3505 pH meter (Jenway, Essex, UK) which was calibrated before use. Buffers were 150 
filtered prior to use through a 0.45 µm Nylon Phenex filter membrane (Phenomenex, Cheshire, 151 
UK) using a Millipore filtration apparatus (Merck Millipore, Hertfordshire, UK).  152 
Compounds were dissolved in methanol at a concentration of 1 mg ml-1. Solutions were diluted 153 
to 0.25 mg ml-1 with deionised water (Barnstead UltraPure) and contained DMSO as the 154 
electroosmotic flow marker (1 % v/v). 155 
DMSO (1 % v/v) in deionised water (Barnstead UltraPure) was run at each pH before 156 
experimental repeats to ensure that an expected electrophoretic mobility was obtained. 157 
Compound migration times were determined using a Beckman Coulter P/ACE MDQ Capillary 158 
Electrophoresis System with a diode array detector (Beckman-Coulter, High Wycombe, UK). 159 
The internal capillary temperature was set at 25 °C using the liquid cooling system. Sample 160 
injection was conducted at 1.0 psi for 10 seconds and then 20 kV voltage was applied during 161 
separations. The capillary was rinsed between each run in the following manner; NaOH applied 162 
at 20 psi for 1.0 minute followed by the appropriate buffer for the next repeat at 20 psi for 2.0 163 
minutes.  164 
Experimentally determined µeff values were obtained using Equation 2. The Microsoft Excel 165 
add-in, Solver, was used to calculate the pKa value using least-squares regression. An initial 166 
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‘best-guess’ estimate for the pKa and α values were used to calculate theoretical effective 167 
mobilities and the squared difference (the residuals) between these theoretical values and 168 
experimental values was then calculated and then minimised by varying the values for pKa and 169 
α. 170 
For pKa measurements, accuracy is defined as a measured value being within 0.20 units from 171 
the literature value and precision is defined as a measured value having a repeatability that is 172 
equal to or less than 0.07 units [35]. Each pKa measurement was repeated in triplicate. 173 
2.2.3. Determination of plasma protein binding 174 
Plasma protein binding values were determined using the commonly-used method of 175 
equilibrium dialysis [37]. 176 
Frozen plasma was thawed at room temperature prior to the experiments. The pH was measured 177 
with a Jenway 3505 pH meter (Jenway, Essex, UK) which was calibrated before use. Plasma 178 
pH was found to be within the physiological range of 7.38 – 7.42 and adjustment was not 179 
required [38]. 180 
PBS tablets were dissolved in deionised water (Barnstead UltraPure) to yield a buffer solution 181 
that contained 0.01M phosphate, 0.0027M KCl, and 0.137M NaCl, pH 7.4 at 25 °C. Stock 182 
solutions of compounds in DMSO at a concentration of 10 mM were created and were diluted 183 
with PBS prior to the experiments to yield working solutions at a concentration of 200 µM.  184 
Reusable Single-Sample Fast Micro-Equilibrium Dialyzers (500 µL volume) were obtained 185 
from Harvard Apparatus (Cambridge, UK), as were cellulose acetate membranes with a 186 
molecular weight cut-off (MWCO) of 10,000 Da.  187 
The membranes were soaked for 30 minutes in deionised water (Barnstead UltraPure) and 188 
rinsed thoroughly. Thirty µL of compound working solution was added to 270 µL of plasma 189 
to yield a final concentration of 20 µM of compound (final DMSO concentration 0.2 %). This 190 
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was placed in one chamber and 500 µL of PBS was placed in the second chamber. The Micro-191 
Equilibrium Dialyzers were then placed into a shaking waterbath held at 37 °C for 24 hours. 192 
The temperature was monitored with a Sentry Thermometer (Fisher Scientific, Leicestershire, 193 
UK). After 24 hours had elapsed, the samples were extracted from each chamber, matrix 194 
matched (with blank plasma or blank buffer). Ice-cold acetonitrile at a 4:1 ratio was then added 195 
to precipitate proteins. The samples were centrifuged at 10,000 rpm for 20 minutes and the 196 
supernatant was recovered and evaporated using a flow of nitrogen with a TurboVap. The 197 
samples were then reconstituted in 200 µL of acetonitrile and analysed using HPLC-DAD. 198 
Details of this analysis are given in Section 2.4. Each plasma protein binding measurement was 199 
repeated in triplicate.  200 
Plasma protein binding (PPB) was calculated using the experimental plasma concentration 201 
(Pexp) and the experimental buffer concentration (Bexp) according to Equation (5). 202 
 𝑃𝑃𝐵 (%) = 100 ×
𝑃𝑒𝑥𝑝 − 𝐵𝑒𝑥𝑝
𝑃𝑒𝑥𝑝
 (5) 
For those benzodiazepines that were highly protein bound and had a concentration in the buffer 203 
phase that was below the limit of quantitation (LOQ), the buffer concentration was calculated 204 
indirectly using Equation (6) which involved the experimental plasma concentration and the 205 
total expected concentration (Ptot), determined using a calibration plot. The total expected 206 
concentration was adjusted using a previously-determined correction factor (CF) for the 207 
extraction efficiency (≈ 95 %). This indirectly-calculated buffer concentration was then input 208 
into Equation (5) to generate plasma protein binding values. 209 
 𝐵𝑒𝑥𝑝 = (𝑃𝑡𝑜𝑡 × 𝐶𝐹) − 𝑃𝑒𝑥𝑝 (6) 
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2.3. Theoretical approaches 210 
Theoretical log D7.4 and pKa values were generated using the free, online software ACD/I-211 
Lab (which makes use of the EPSRC funded National Chemical Database Service hosted by 212 
the Royal Society of Chemistry) and two commercial software packages; MarvinSketch 213 
(version 17.28.0) (ChemAxon) and ADMET Predictor (Simulations Plus). Theoretical plasma 214 
protein binding values were obtained from two sources used for log D7.4 and pKa; ACD/I-Lab 215 
and ADMET Predictor (Simulations Plus) and one source available as a free online resource, 216 
PreADMET (version 2.0). These software packages are all commonly used for the prediction 217 
of physicochemical and pharmacokinetic parameters [39–42]. Theoretical values were 218 
compared with experimental values by means of the absolute difference in values. 219 
2.4. HPLC analysis for log D7.4 and plasma protein binding 220 
Analysis was achieved with a Dionex UltiMate 3000 HPLC system equipped with an UltiMate 221 
3000 Pump, UltiMate 3000 Autosampler, UltiMate 3000 Column Compartment, UltiMate 222 
3000 Photodiode Array Detector and Chromeleon software (Dionex, Surrey, UK). Separation 223 
was achieved with a Waters® Spherisorb® analytical cartridge, C18 5 µm 80 Å (4.6 × 150 224 
mm) with an attached guard cartridge identically packed to the analytical cartridge (Waters, 225 
Hertfordshire, UK). The internal column temperature was kept constant at 25 °C and a flow 226 
rate of 0.8 mL min-1 was set. Injection volumes for the log D7.4 experiments were 25 µL for the 227 
octanol phase and 100 µL for the phosphate buffer phase so that a dilution step was not 228 
necessary. Compound concentrations were retrospectively corrected. Injection volumes of 100 229 
µL were used for the plasma protein binding experiments. A 46:54 (v/v) ratio of acetonitrile 230 
and sodium phosphate buffer (pH 3.0, 25 mM) was applied for 25 minutes. All compounds 231 
eluted within this time. The eluent was monitored by UV detection at 230 nm. Details of the 232 
method validation can be found in the Supplementary Information. 233 
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3. Results and discussion 234 
Experimental log D7.4, pKa and plasma protein binding values for all the classic and NPS- 235 
benzodiazepines were successfully determined and compared with theoretical values. 236 
3.1.Experimental values 237 
3.1.1. Log D7.4 238 
Buffer composition is important for the determination of log D7.4 values. Use of a 0.01 M 239 
phosphate buffer has been shown to give an excellent correlation of distribution coefficients 240 
determined in the octanol-phosphate system for acidic and neutral compounds [43]. Despite 241 
the basic nature of the compounds in this study, a 0.01 M sodium phosphate buffer (pH 7.4) 242 
was chosen and its suitability evaluated by way of a comparison between the experimental log 243 
D7.4 values and literature log D7.4 values. 244 
For the clinically-used (and previously characterised) benzodiazepines the experimental results 245 
obtained for log D7.4 in this study were very close to those reported elsewhere in the literature, 246 
thus proving the suitability of this method and also the use of the 0.01 M sodium phosphate 247 
buffer (pH 7.4) (Table 1).  248 
The majority of the NPS-benzodiazepines were fairly lipophilic with log D7.4 values above 2 249 
(Table 1). None of the NPS-benzodiazepines had literature-reported log D7.4 values other than 250 
desalkylflurazepam with 2.78 versus a value of 2.82 in this work. Phenazepam (log D7.4 of 251 
3.25) was observed to be the most lipophilic NPS-benzodiazepine in this dataset while 252 
pyrazolam (log D7.4 of 0.97) was the least lipophilic, a 190-fold difference. The reason behind 253 
the low lipophilicity for pyrazolam becomes more apparent when its structure is considered. 254 
Pyrazolam contains a pyridin-2-yl ring at position 7 rather than a phenyl ring, as is the case 255 
with the rest of the benzodiazepines in this study. The phenyl ring has a log D7.4  value of 1.56 256 
versus a log D7.4 value of 0.62 for the pyridin-2-yl ring [44]. Replacement of a phenyl ring for 257 
a pyridin-2-yl ring could lead to a decrease in lipophilicity. The benzodiazepine bromazepam 258 
contains a pyridin-2-yl ring rather than a phenyl ring and has a log D7.4 value of 1.60 [45]. The 259 
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addition of a triazole ring to some compounds is also known to lead to a decrease in the partition 260 
coefficient [46][47]. The pyridin-2-yl ring and triazole ring addition appear to lead to a marked 261 
decrease in lipophilicity for pyrazolam. Previous research has used log D7.4 values in a 262 
quantitative structure-activity relationship (QSAR) model which predicted the post-mortem 263 
distribution of benzodiazepines and was found to contribute significantly to their distributive 264 
potential [48]. Log D7.4 has also been utilised, along with plasma protein binding and pKa, to 265 
derive models capable of predicting the volume of distribution at steady state of a wide range 266 
of compounds [49,50].   267 
3.1.2. pKa 268 
Experimental pKa values were all within 0.20 units of their literature values for the classic 269 
benzodiazepines and had excellent repeatability, under 0.07 units for all the reference 270 
compounds (Table 2). Classic benzodiazepines either have one pKa value, for example 271 
flunitrazepam (1.8), or two clonazepam (1.5 and 10.5) [51,52]. The first pKa value refers to the 272 
deprotonation of the nitrogen cation at position 4 and the second pKa refers to the deprotonation 273 
of the nitrogen atom at position 1 [51]. The deprotonation of the nitrogen atom at position 1 is 274 
thought to be resonance stabilised with the negatively-charged oxygen atom [51]. This can be 275 
visualised in Figure 1 for clonazepam. 276 
Figure 1. The two sites of deprotonation and corresponding pKa values for clonazepam  277 
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Values of 2.83 for etizolam and 2.51 and 11.64 for desalkylflurazepam were calculated in this 278 
work. These compared favourably to their previously-reported values of 2.76 for etizolam and 279 
of 2.57 and 11.76 for desalkylflurazepam [53,54]. 280 
The presence of an electron-withdrawing hydroxyl group decreases the pKa2 value, as does the 281 
presence of an ortho-chlorine substituent on the phenyl ring [55]. Clonazepam has this ortho-282 
chlorine substituent and has a calculated pKa value of 1.55 in this work. 3-283 
Hydroxyphenazepam, in addition to an ortho-chlorine substituent, also has a hydroxyl group 284 
and therefore its low pKa value of 1.25 was not unexpected. Repeatability was generally good 285 
for the NPS-benzodiazepines; 0.07 is typically the expected variance in capillary 286 
electrophoresis measurements [35]. However, a variance of up to ±0.10 was observed for some 287 
compounds including 3-Hydroxyphenazepam. This could be as a result of its pKa1 value (1.25) 288 
being lower than the pH of the lowest buffer used (1.50).  289 
3.1.3. Plasma protein binding 290 
A number of the benzodiazepines had concentrations in the buffer phase would have been 291 
below the limit of quantitation (LOQ), these were; diazepam, oxazepam, prazepam, 4’-292 
Chlorodiazepam, flubromazepam and phenazepam. All concentrations were higher than the 293 
limit of detection (LOD). As mentioned in the methods section the buffer phase concentrations 294 
were calculated indirectly. The use of a correction factor is less desirable than direct 295 
measurements however, it did not appear to affect the calculated values for plasma protein 296 
binding when compared with literature values (Table 3).  297 
Values for plasma protein binding are listed in Table 3 for clinically used benzodiazepines; 298 
wide variations were reported in the literature for many of the benzodiazepines. Age and sex 299 
have both been observed as causing differences in the plasma protein binding of drugs which 300 
may have been a factor in these variations as many of them were determined in vivo [56–58].  301 
The experimentally derived values for the reference benzodiazepines were typically within the 302 
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literature ranges with low variations. The majority of the NPS-benzodiazepines were observed 303 
to exhibit a high degree of plasma protein binding (> 90 %), i.e. similar to the clinically used 304 
benzodiazepines (Table 3). Literature values for the plasma protein binding of three NPS-305 
benzodiazepines were available and experimental values derived in this work returned a 306 
consensus with these; desalkylflurazepam (experimental 95.5 % versus 96.1 – 96.5 % 307 
literature), etizolam (experimental 92.8 % versus 93 % literature) and flubromazolam 308 
(experimental 89.5 % versus literature 89 %) [24,59–61].  309 
The lowest plasma protein binding was observed for pyrazolam which was 78.7 %. Such a low 310 
value of plasma protein binding for a benzodiazepine is not unheralded as bromazepam has a 311 
reported 60 % plasma protein binding [31]. Substitution of the phenyl ring at position-5 for a 312 
pyridin-2-yl ring has been previously reported to lead to a large decrease in lipophilicity for 1,-313 
4-benzodiazepines [59]. The same effect could well occur for triazolobenzodiazepines.  314 
4’-Chlorodiazepam differs from diazepam by having an additional chlorine atom substituted at 315 
the 4’-position of the phenyl ring and exhibits similarly high plasma protein binding; 98.2 % 316 
versus 99.0 % for diazepam. Diclazepam is an isomer of 4’-Chlorodiazepam; identical in 317 
chemical formula but differing in structure with the chlorine atom being substituted at the 2’-318 
position of the phenyl ring. Its plasma protein binding value was calculated as being 93.8 %, 319 
lower than diazepam or 4’-Chlorodiazepam. However diclazepam’s demethylated metabolite 320 
has been reported as having a plasma protein binding of 94.9 % and demethylation at the 1-321 
position is not thought to substantially affect plasma protein binding [59]. Therefore, it stands 322 
to reason that the decreased plasma protein binding observed is most likely as a result of the 323 
substitution of a chlorine atom at the 2’-position. Substitution at the 2’-position with a chlorine 324 
atom has been observed to decrease plasma protein binding but if this substitution instead 325 
occurs at the 4’ position then no such decrease is observed [59]. This is thought to be as a result 326 
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of the substitution at the 2’-position affecting the rotation and orientation of the benzene ring 327 
and resulting in lower binding.  328 
3-Hydroxyphenazepam exhibited lower plasma protein binding than its parent compound, 329 
phenazepam; 97.7 % versus 98.3 % and this is consistent with observations that hydroxylation 330 
at the 3-position leads to a decrease in plasma protein binding [59]. Deschloroetizolam has a 331 
reduced plasma protein binding compared to the thienotriazolodiazepine etizolam (87.2 % 332 
versus 92.8%). Removal of a chlorine atom from position-7 has been found to decrease plasma 333 
protein binding for 1,4-benzodiazepines and a similar relationship may hold true for 334 
thienotriazolodiazepines [59].  335 
Desalkylflurazepam differs from flubromazepam by replacement of the bromine atom at the 7-336 
position by a chlorine atom. Its plasma protein binding is lower (95.5 % versus 96.2 %) which 337 
is consistent with literature observations that this replacement causes a decrease in plasma 338 
protein binding [59].  339 
Phenazepam differs from flubromazepam by replacement of the fluorine atom at the 2’-position 340 
with a chlorine atom and exhibits an increase in plasma protein binding from 96.4 % to 98.3 341 
%. Again, this is consistent with previous literature observations on 1,4-benzodiazepines [59]. 342 
3.2. Theoretical values 343 
3.2.1. Log D7.4 344 
ACD/I-Lab returned the closest predicted log D7.4 values to the experimental values for both 345 
the eight test benzodiazepines (average absolute error 0.18) and the 11 NPS-benzodiazepines 346 
(average absolute error 0.28). ADMET Predictor returned the next-closest predicted values 347 
with average absolute errors of 0.24 for the test benzodiazepines and 0.37 for the NPS-348 
benzodiazepines. MarvinSketch fared the worst, returning an average absolute error of 0.39 for 349 
the test benzodiazepines and 0.97 for the NPS-benzodiazepines. It is therefore clear that all 350 
three programs had a lower accuracy in predicting the log D7.4 for the NPS-benzodiazepines 351 
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and this highlights the importance of the collection of experimental data especially if these 352 
models are to be improved. An example of this is for pyrazolam, with an experimental value 353 
of 0.97 yet ACD/I-Lab returned a value of 1.76, i.e. approximately a six-fold difference in 354 
apparent lipophilicity. The atypical structure of pyrazolam, with its pyridin-2-yl ring, possibly 355 
led to these large differences. Inclusion of pyrazolam along with the other NPS-356 
benzodiazepines in any future training dataset for these predictive models could possibly assist 357 
in the prediction of log D7.4. 358 
3.2.2. pKa 359 
ADMET Predictor returned the closest predicted values to experimental values, with an 360 
absolute average error of 0.4 for both the test set and the NPS set. This was closely followed 361 
by ACD/I-Lab which returned absolute average errors of 0.5 for both sets. MarvinSketch 362 
returned average absolute errors of 0.6 for the test set and 0.7 for the NPS set. MarvinSketch 363 
did not predict pKa1 values for oxazepam and temazepam and instead predicted two pKa2 364 
values for oxazepam (only one of which exists) and one pKa2 value for temazepam (only a 365 
pKa1 value is observed). Large errors were observed in some of the pKa values returned by the 366 
software. For example; a pKa of 2.45 predicted by ACD/I-Lab for deschloroetizolam versus an 367 
experimental pKa of 4.19, a pKa of 1.33 predicted by MarvinSketch for etizolam versus an 368 
experimental pKa of 2.80 and a pKa of 2.98 predicted for flubromazolam by ADMET Predictor 369 
versus an experimental pKa of 2.07. Additionally, all three software packages predicted 370 
multiple other deprotonation sites for some of the benzodiazepines which are not 371 
experimentally observed. The importance of obtaining accurate experimental pKa values is 372 
therefore clear especially if these predictive models wish to be improved upon. 373 
3.2.3. Plasma protein binding 374 
Plasma protein binding was best predicted by ACD/I-Lab which returned average absolute 375 
errors of 4.4 % for the test benzodiazepines and 3.0 % for the NPS-benzodiazepines. ADMET 376 
Predictor followed closely behind with average absolute errors of 6.8 % for the test 377 
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benzodiazepines and 3.4 % for the NPS-benzodiazepines. PreADMET returned average 378 
absolute errors of 9.9 % for the test benzodiazepines and 5.0 % for the NPS-benzodiazepines. 379 
The software appeared to be less effective at predicting plasma protein binding of the test 380 
benzodiazepines than the NPS-benzodiazepines (Table 3). However an important caveat is that 381 
the average absolute errors for the test benzodiazepines were influenced heavily by the small 382 
dataset and the presence of alprazolam; the experimental plasma protein binding was 383 
determined as being 71.6 % and the predicted values were 89.5 % (ACD/I-Lab), 91.2 % 384 
(ADMET Predictor) and 95.2% (PreADMET). Again, inclusion of a wider range of 385 
benzodiazepines (especially those with aberrant structures such as pyrazolam) in any training 386 
dataset may assist with their predictive power. 387 
4. Conclusions 388 
Log D7.4, pKa and plasma protein binding values were successfully determined in this work for 389 
a range of benzodiazepines that have emerged as novel psychoactive substances. The 390 
experimental methods presented were judged to be suitably accurate for the determination of 391 
these values.  392 
Large variations in plasma protein binding and log D7.4 were observed for the NPS-393 
benzodiazepines. Pyrazolam was found to be the least lipophilic NPS-benzodiazepine with a 394 
log D7.4 of 0.97 and experienced the lowest plasma protein binding of 78.7 %. Phenazepam was 395 
the most lipophilic NPS-benzodiazepine with a log D7.4 of 3.25 and a plasma protein binding 396 
of 98.3 %. 3-Hydroxyphenazepam had the lowest pKa1 value of 1.25 while deschloroetizolam 397 
had the highest pKa1 value of 4.19. Phenazepam had the lowest pKa2 value of 11.24 and 3-398 
Hydroxyphenazepam had the highest of 11.96. 399 
ACD/I-Lab returned the closest predicted values to experimental values for both plasma protein 400 
binding and log D7.4 while ADMET Predictor returned the closest predicted values to 401 
experimental values for pKa. Although the average errors returned by each software package 402 
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were often low, there were large variations in individual errors. It is therefore likely that 403 
experimental data for these novel psychoactive substances remains preferable to that generated 404 
from predictive software. The inclusion of experimental data for these NPS-benzodiazepines 405 
could aid the predictive capability of various software packages.406 
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Table 1. Literature, experimental (n= ≥3) and theoretical log D7.4 values for a set of classic and NPS-benzodiazepines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Literature log D7.4 Experimental log D7.4 
Theoretical log D7.4 
References 
ACD/I-
LAB/I-
lab 
MarvinSketch 
ADMET 
Predictor 
Benzodiazepines 
Alprazolam 2.12 – 2.16 2.10 ±0.01 2.44 3.02 2.63 [62,63] 
Clonazepam 2.41 2.40 ±0.02 2.57 3.15 2.49 [45,62] 
Diazepam 2.79 – 2.99 2.81 ±0.03 2.87 3.08 2.96 [45,62–64] 
Flunitrazepam 2.06 – 2.14 2.05 ±0.01 2.20 2.55 1.87 [45,62,63] 
Nitrazepam 2.13 – 2.16 2.17 ±0.03 2.03 2.55 2.49 [45,62] 
Oxazepam 2.13 – 2.24 2.24 ±0.05 2.04 2.92 1.95 [17,45] 
Prazepam 3.7 – 3.73 3.74 ±0.04 3.84 3.86 3.68 [45,62] 
Temazepam 1.79 – 2.19 2.32 ±0.01 2.13 2.79 2.18 [45,62] 
NPS-benzodiazepines 
3-Hydroxyphenazepam Not reported 2.54 ±0.01 2.67 3.69 2.40 Not reported 
4’-Chlorodiazepam Not reported 2.75 ±0.08 3.13 3.68 3.40 Not reported 
Desalkylflurazepam 2.70 2.82 ±0.09 2.71 3.15 2.74 [62] 
Deschloroetizolam Not reported 2.60 ±0.03 2.43 3.45 2.82 Not reported 
Diclazepam Not reported 2.73 ±0.02 3.13 3.68 3.25 Not reported 
Etizolam Not reported 2.40 ±0.01 2.74 4.06 3.32 Not reported 
Flubromazepam Not reported 2.87 ±0.05 2.96 3.52 2.80 Not reported 
Flubromazolam Not reported 2.40 ±0.04 2.52 3.33 2.60 Not reported 
Meclonazepam Not reported 2.64 ±0.05 2.91 3.72 2.80 Not reported 
Phenazepam Not reported 3.25 ±0.04 3.52 3.98 3.19 Not reported 
Pyrazolam Not reported 0.97  ±0.01 1.76 2.36 2.03 Not reported 
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Table 2. Literature, experimental (n= ≥3) and theoretical pKa values for a set of classic and NPS benzodiazepines 
 
 
 
Compound 
Literature pKa Experimental pKa 
Theoretical pKa 
References 
ACD/I-LAB/I-
lab 
MarvinSketch ADMET Predictor 
pKa1 pKa2 pKa1 pKa2 pKa1 pKa2 pKa1 pKa2 pKa1 pKa2 
Benzodiazepines 
Alprazolam 2.4 None 2.48 ±0.01 None 2.37 None 
1.45, 
5.01 
None 0.93, 3.01 None [65] 
Clonazepam 1.49 – 1.52 
10.37 – 
10.51 
1.55 ±0.02 10.45 ±0.05 1.55 11.21 1.89 11.65 1.43 10.77 [65–67] 
Diazepam 3.17 – 3.31 None 3.10 ±0.00 None 3.40 None 2.92 None 2.96 None [66,68] 
Flunitrazepam 1.8 None 1.82 ±0.04 None 1.68 None 1.72 None 1.87 None [65] 
Nitrazepam 2.94 – 3.2 10.8 – 11 3.11 ±0.06 11.02 ±0.05 2.55 11.35 2.65 11.66 2.49 11.02 [55,66] 
Oxazepam 1.56 – 1.7 11.21 – 11.6 1.67 ±0.05 11.34 ±0.03 1.17 
10.94, 
12.75 
None 
10.65, 
12.47 
2.57 11.31 [66,67] 
Prazepam 2.7 – 2.74 None 2.71 ±0.01 None 3.44 None 3.06 None 3.10 None [65,66] 
Temazepam 1.31 – 1.6 None 1.45 ±0.05 None 1.58 11.66 None 10.68 2.48 None [66,69] 
NPS-benzodiazepines 
3-Hydroxyphenazepam Not reported Not reported 1.25 ±0.10 11.96 ±0.09 0.13 
10.80, 
12.68 
None 
10.61, 
12.45 
1.95 11.24 Not reported 
4’-Chlorodiazepam Not reported Not reported 3.13 ±0.01 None 3.08 None 2.45 None 2.55 None Not reported 
Desalkylflurazepam 2.57 11.76 2.51 ±0.05 11.64 ±0.04 2.36 11.55 1.80 12.29 2.31 11.37 [53]  
Deschloroetizolam Not reported Not reported 4.19 ±0.01 None 
0.20, 
2.45 
None 
1.31, 
5.37 
None 1.84, 3.96 None Not reported 
Diclazepam Not reported Not reported 2.31 ±0.07 None 1.75 None 2.13 None 1.95 None Not reported 
Etizolam 2.76 None 2.83 ±0.06 None 
0.10, 
2.37 
None 
1.33, 
4.55 
None 1.61, 3.31 None [54] 
Flubromazepam Not reported Not reported 3.25 ±0.10 10.74 ±0.05 2.32 11.55 1.8 12.28 2.70 11.45 Not reported 
Flubromazolam Not reported Not reported 2.07 ±0.02 None 2.27 None 
1.48, 
4.01 
None 0.96, 2.98 None Not reported 
Meclonazepam Not reported Not reported 2.10 ±0.09 11.45 ±0.07 1.70 11.24 1.65 11.57 2.10 10.88 Not reported 
Phenazepam Not reported Not reported 2.19 ±0.05 11.21 ±0.04 2.18 11.58 2.06 12.28 2.44 11.43 Not reported 
Pyrazolam Not reported Not reported 3.30 ±0.03 None 
1.30, 
2.18 
None 
1.79, 
2.75 
None 
0.65, 2.47, 
3.21 
None Not reported 
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Table 3. Literature, experimental (n= ≥3) and theoretical plasma protein binding (PPB) values for a set of classic and NPS benzodiazepines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Literature PPB (%) Experimental PPB (%) 
Theoretical PPB (%) 
References ACD/
I-lab 
ADMET 
Predictor 
PreADMET 
Benzodiazepines 
Alprazolam 68.4 – 76.7 71.6 ±0.5 89.5 91.2 95.2 [31,70] 
Clonazepam 85.4 – 86.1 85.5 ±1.2 91.9 90.9 93.3 [31,70] 
Diazepam 98.4 – 99 99.0 ±0.2 96.5 93.2 98.7 [31,37] 
Flunitrazepam 77.5 – 84.5 78.9 ±1.2 84.4 86.5 98.9 [31,70] 
Nitrazepam 82.1 – 88.9 88.4 ±1.8 88.5 84.3 92.0 [71,72] 
Oxazepam 89.0 – 98.4 96.9 ±0.1 95.6 88.9 96.7 [31,70] 
Prazepam ≈97 97.4 ±0.5 97.7 96.5 94.0 [73] 
Temazepam 92 – 96.8 94.3 ±0.1 95.4 91.1 74.3 [31,70] 
NPS-benzodiazepines 
3-Hydroxyphenazepam Not reported 97.7 ±0.6 92.5 93.8 90.1 Not reported 
4’-Chlorodiazepam Not reported 98.2 ±0.5 96.5 96.2 93.2 Not reported 
Desalkylflurazepam 96.1 – 96.5 95.5 ±1.5 96.1 92.8 91.4 [60] 
Deschloroetizolam Not reported 87.2 ±1.5 85.8 91.5 89.8 Not reported 
Diclazepam Not reported 93.8 ±1.2 96.5 95.7 97.7 Not reported 
Etizolam Not reported 92.8 ±0.6 90.2 94.7 90.8 Not reported 
Flubromazepam Not reported 96.4 ±0.9 89.0 93.2 93.9 Not reported 
Flubromazolam 89 89.5 ±0.4 87.4 91.1 92.2 [24] 
Meclonazepam Not reported 88.2 ±0.5 93.0 93.0 92.3 Not reported 
Phenazepam Not reported 98.3 ±1.2 94.6 95.6 93.6 Not reported 
Pyrazolam Not reported 78.7 ±0.4 77.6 86.5 94.8 Not reported 
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Supplementary information 
Benzodiazepine structures 
The structures of the NPS-benzodiazepines used in this work are visualised in Figures S1A – C and Tables S1 – 
3. 
A) 1,4-benzodiazepine 
 
B) Triazolobenzodiazepine
 
C) Thienotriazolodiazepine 
 
Figures S1A – C. Basic structure of a 1,4-benzodiazepine, a triazolobenzodiazepine and a 
thienotriazolodiazepine  
Table S1. Substituents for 1,4-benzodiazepines 
 From Figure 1A 
Compound R1 R2’ R3 R7 
3-Hydroxyphenazepam H Cl OH Br 
4-Chlorodiazepam (Ro5-
4864)a 
CH3 H H Cl 
Desalkylflurazepam H F H Cl 
Diclazepam CH3 Cl H NO2 
Flubromazepam H F H Br 
Meclonazepam H Cl CH3 NO2 
Phenazepam H Cl H Br 
a Note:  4-Chlorophenyl ring instead of phenyl ring at position 6 
 
Table S2. Substituents for triazolobenzodiazepines 
 From Figure 1B 
Compound R1 R2’ R8 
Flubromazolam CH3 F Br 
Pyrazolama 
 
CH3 None Br 
a Note: pyridine ring instead of phenyl ring at position 6 
 
Table S3. Substituents for thienotriazolodiazepines 
 From Figure 1C 
Compound R2 R2’ R9 
Deschloroetizolam CH2CH3 H CH3 
Etizolam CH2CH3 Cl CH3 
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HPLC Method validation 
The method was validated in terms of linearity, limit of quantitation (LOQ), limit of detection (LOD), accuracy 
and precision. This was performed according to the ICH guidelines. 
Linearity 
The linearity of this method was measured by constructing a five-point calibration plot of the area under the curve 
(AUC) of each compound against its concentration in mg ml-1 (n=3). The method was linear over the concentration 
range 0.0004 – 0.25 mg ml-1 for all compounds. The residual sum of squares for each compound was reasonably 
low indicating linear concentration-response and a suitable method (Table S4). 
Limit of detection (LOD) and limit of quantitation (LOQ) 
The limits of detection and quantitation were determined from the signal-to-noise ratio. The baseline response of 
blank samples was recorded. A ratio of 10:1 for the compound response to the baseline response was used for the 
LOQ and a ratio of 3:1 for the LOD. All compounds generally had good limits of detection and quantitation (Table 
S4). Pyrazolam exhibited the lowest response to the HPLC method, with a LOQ of 263.9 ng ml-1 and a LOD of 
82.0 ng ml-1. 
Accuracy 
Accuracy was determined through comparison of the percentage recovery at three concentrations (0.25, 0.01 and 
0.0004 mg ml-1). Percentage recovery was generally within 2 % and thus deemed to be acceptable (Table 5). 
Precision 
Precision was determined from the calculation of the standard deviation and relative standard deviation (RSD) of 
the compound peak areas at three concentrations (0.25, 0.01 and 0.0004 mg ml-1). High levels of precision for all 
benzodiazepines were recorded (Table S5). 
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Table S4. Linearity, LOQ and LOD data for benzodiazepines 
Compound Slope Correlation 
coefficient 
y intercept Residual 
sum of 
squares 
LOQ  
(ng ml-1) 
LOD 
(ng ml-1) 
3-Hydroxyphenazepam 4455.57 1.00 -0.55 19.40 188.9 42.9 
4’-Chlorodiazepam 4819.30 1.00 1.44 11.30 202.2 59.5 
Alprazolam 4826.85 1.00 1.36 27.07 144.6 49.8 
Clonazepam 4407.07 1.00 0.37 21.90 185.4 59.2 
Desalkylflurazepam 4283.08 1.00 -0.74 16.43 187.2 53.4 
Deschloroetizolam 4072.89 1.00 0.86 13.00 206.1 62.5 
Diazepam 4758.95 1.00 -0.74 18.41 185.5 51.8 
Diclazepam 4817.39 1.00 0.48 12.73 198.8 59.9 
Etizolam 4007.71 1.00 0.51 13.20 194.2 57.0 
Flubromazepam 4084.79 1.00 0.73 15.99 165.6 67.6 
Flubromazolam 4168.69 1.00 -0.42 10.68 177.3 47.2 
Flunitrazepam 4223.77 1.00 -0.92 13.05 159.0 51.5 
Meclonazepam 4805.99 1.00 0.87 9.15 186.4 52.5 
Nitrazepam 4367.07 1.00 -0.37 10.82 179.2 49.4 
Oxazepam 4466.93 1.00 -0.53 7.17 159.8 50.2 
Phenazepam 4149.34 1.00 -0.17 11.76 191.2 65.3 
Prazepam 4338.90 1.00 0.34 9.32 172.3 56.0 
Pyrazolam 3967.82 1.00 -0.31 14.76 263.9 82.0 
Temazepam 4646.75 1.00 -0.34 9.67 195.6 51.9 
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Table S5. Precision and accuracy data for benzodiazepines 
 
 
 
 
Compound 
Concentration (mg ml-1) 
0.0004 (n=3) 0.01 (n=3) 0.25 (n=3) 
Precision 
SD 
Precision 
RSD (%) 
Accuracy (%) 
Precision SD  
Precision 
RSD (%) 
Accuracy (%) 
Precision SD 
Precision 
RSD (%) 
Accuracy (%) 
3-Hydroxyphenazepam 0.04 2.08 99.39 0.53 1.17 100.46 8.88 0.80 99.17 
4’-Chlorodiazepam 0.06 1.72 101.35 0.47 0.93 101.85 10.29 0.85 100.54 
Alprazolam 0.04 1.31 99.49 0.88 1.75 100.57 13.44 1.10 99.86 
Clonazepam 0.05 1.53 101.11 0.81 1.62 99.25 6.91 1.77 99.98 
Desalkylflurazepam 0.02 1.10 98.60 0.27 0.62 101.50 7.16 0.66 101.12 
Deschloroetizolam 0.04 1.58 99.25 0.24 0.57 99.56 5.81 0.57 100.68 
Diazepam 0.02 1.16 98.90 0.59 1.24 100.98 11.69 0.97 101.23 
Diclazepam 0.02 0.70 98.92 0.54 1.07 101.49 6.46 0.54 99.10 
Etizolam 0.04 1.74 98.99 0.72 1.78 99.57 9.95 1.00 99.73 
Flubromazepam 0.03 1.16 99.21 0.66 1.56 101.76 5.36 0.52 101.34 
Flubromazolam 0.03 2.15 100.41 0.55 1.13 100.89 17.93 1.71 100.74 
Flunitrazepam 0.06 2.03 98.97 0.27 0.55 99.56 9.33 0.78 99.72 
Meclonazepam 0.02 0.81 99.43 0.31 0.63 100.35 8.49 0.71 99.46 
Nitrazepam 0.02 1.21 98.20 0.54 1.10 100.15 9.67 0.78 100.83 
Oxazepam 0.02 1.44 101.76 0.70 1.56 101.68 7.48 0.68 99.21 
Phenazepam 0.03 2.17 101.01 0.98 2.37 99.95 6.45 0.62 100.23 
Prazepam 0.05 2.15 98.63 0.67 1.54 99.78 6.51 1.66 99.51 
Pyrazolam 0.03 2.14 99.47 0.53 1.33 101.53 2.95 0.30 100.73 
Temazepam 0.03 2.05 101.74 0.65 1.40 101.27 13.64 1.18 99.55 
